Risk of Acute Myocardial Infarction Among New Users of Allopurinol According to Serum Urate Level: A Nested Case-Control Study
by
Sara Rodríguez-Martín 1,2,†
, Francisco J. de Abajo 1,2,*,†, Miguel Gil 3, Diana González-Bermejo 3, Antonio Rodríguez-Miguel 1,2, Diana Barreira-Hernández 1,2, 
Ramón Mazzucchelli 4, Alberto García-Lledó 5,6 and Luis A. García-Rodríguez 7
Sara Rodríguez-Martín 1,2,†, Francisco J. de Abajo 1,2,*,†, Miguel Gil 3, Diana González-Bermejo 3, Antonio Rodríguez-Miguel 1,2, Diana Barreira-Hernández 1,2, Ramón Mazzucchelli 4, Alberto García-Lledó 5,6 and Luis A. García-Rodríguez 7
1
Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, 28805 Madrid, Spain
2
Department of Biomedical Sciences (Pharmacology Sector), University of Alcalá (IRYCIS), Alcalá de Henares, 28805 Madrid, Spain
3
Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices (AEMPS), 28022 Madrid, Spain
4
Department of Rheumatology, University Hospital Fundación Alcorcón, 28922 Alcorcón, Madrid, Spain
5
Department of Cardiology, University Hospital Príncipe de Asturias, Alcalá de Henares, 28805 Madrid, Spain
6
Department of Medicine, University of Alcalá, Alcalá de Henares, 28805 Madrid, Spain
7
Spanish Center for Pharmacoepidemiologic Research (CEIFE), 28004 Madrid, Spain
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to the study.
J. Clin. Med. 2019, 8(12), 2150; https://doi.org/10.3390/jcm8122150
Received: 24 November 2019 / Accepted: 3 December 2019 / Published: 5 December 2019
(This article belongs to the Section Pharmacology)
Objectives: To test the hypothesis that allopurinol reduces the risk of acute myocardial infarction (AMI) in hyperuricemic patients and to assess whether the effect is dependent on dose, duration and serum uric acid (SUA) level attained after treatment. Methods: Nested case-control study over the period 2002–2015. From a cohort of patients aged 40–99 years old, we identified incident AMI cases and randomly selected five controls per case, matched for exact age, sex and index date. Adjusted odds ratios (AOR) and 95% CI were computed through unconditional logistic regression. Only new users of allopurinol were considered. Results: A total of 4697 AMI cases and 18,919 controls were included. Allopurinol use was associated with a reduced risk of AMI mainly driven by duration of treatment (AOR ≥180 days = 0.71; 95% CI: 0.60–0.84). Among long-term users (≥180 days), the reduced risk was only observed when the SUA level attained was below 7 mg/dL (AOR<6 mg/dL = 0.64; 95% CI: 0.49–0.82; AOR6–7mg/dL = 0.64; 95%CI:0.48-0.84); AOR>7mg/dL = 1.04; 95% CI: 0.75–1.46; p for trend = 0.001). A dose-effect was observed but faded out once adjusted for the SUA level attained. The reduced risk of AMI occurred in both patients with gout and patients with asymptomatic hyperuricemia. Conclusions: The results confirm a cardioprotective effect of allopurinol which is strongly dependent on duration and SUA level attained after treatment.
View Full-Text
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Rodríguez-Martín, S.; de Abajo, F.J.; Gil, M.; González-Bermejo, D.; Rodríguez-Miguel, A.; Barreira-Hernández, D.; Mazzucchelli, R.; García-Lledó, A.; García-Rodríguez, L.A. Risk of Acute Myocardial Infarction Among New Users of Allopurinol According to Serum Urate Level: A Nested Case-Control Study. J. Clin. Med. 2019, 8, 2150.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
